Confluent Medical Technologies Announces Grand Opening of Costa Rica Expansion

Confluent Medical Technologies Announces the Grand Opening of the Newest Building at Their Large Scale Manufacturing Center of Excellence in Alajuela, Costa Rica

Confluent Medical Technologies today announced the Grand Opening of the latest addition to their large-scale manufacturing center of excellence in Alajuela, Costa Rica, expanding their capacity for Nitinol processing and catheter manufacturing.

This new facility will be co-located with the existing Confluent Medical Technologies Costa Rica facility and will add an additional 66,000 square feet to this location. The new site greatly expands Confluent’s capacity to process Nitinol components, as well as produce complex catheters using a combination of clean rooms and white-space manufacturing.

“Confluent has experienced consistent and strong growth in recent years,” says Confluent President & CEO Dean Schauer. “This expansion supports our new product pipeline which continues to grow at a rate greater than Confluent has previously experienced.”

Confluent Medical Technologies supports some of the fastest growing medical device markets such as Interventional Neurovascular, Electrophysiology, Structural Heart, and Peripheral Vascular. As a result of the double-digit growth of these currently served markets, a substantial number of new products are coming into production and will utilize this new facility space immediately. Additionally, Confluent is considering additional expansion options beyond this new facility.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy